Roche is offering $400 million upfront and over $15 billion in biobucks to team up with Hansoh Pharmaceutical in hopes of developing a portfolio of new antibody-drug conjugates using the latter’s in-house tech.
Roche is offering $400 million upfront and over $15 billion in biobucks to team up with Hansoh Pharmaceutical in hopes of developing a portfolio of new antibody-drug conjugates using the latter’s in-house tech.